Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 2, 2016, Pages 444-451.e8

  Demoly, Pascal ^a   Emminger, Waltraud ^b   Rehm, Dorte ^c   Backer, Vibeke ^d   Tommerup, Lene ^c   Kleine Tebbe, Jörg ^e  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b Allergy Outpatient Clinic   (Austria)

^c ALK ABELLÓ   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e Outpatient Clinic   (Germany)

Author keywords

allergen immunotherapy; allergic rhinitis; allergy; Allergy immunotherapy; house dust mite; Rhinitis Quality of Life Questionnaire; rhinoconjunctivitis; sublingual immunotherapy; sublingual immunotherapy tablet; total combined rhinitis score

Indexed keywords

HOUSE DUST ALLERGEN; PLACEBO; ALLERGEN;

ADULT; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; COUGHING; DERMATOPHAGOIDES; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; HUMAN; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; MULTICENTER STUDY; ORAL PRURITUS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATOLOGY; THROAT IRRITATION; TOTAL COMBINED RHINITIS SCORE; TREATMENT DURATION; ADOLESCENT; AGED; ANIMAL; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; PYROGLYPHIDAE; RHINITIS, ALLERGIC; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; PYROGLYPHIDAE; RHINITIS, ALLERGIC; RISK FACTORS; SUBLINGUAL IMMUNOTHERAPY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957962136     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.06.036     Document Type: Article

References (40)

1. V. Bauchau, and S.R. Durham Prevalence and rate of diagnosis of allergic rhinitis in Europe Eur Respir J 24 2004 758 764
2. P.J. Bousquet, S. Chinn, C. Janson, M. Kogevinas, P. Burney, and D. Jarvis Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I Allergy 62 2007 301 309
3. A. Linneberg, N. Henrik Nielsen, L. Frolund, F. Madsen, A. Dirksen, and T. Jorgensen The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study Allergy 57 2002 1048 1052
4. M.A. Calderon, A. Linneberg, J. Kleine-Tebbe, B.F. de, R.D. Hernandez Fernandez de, J.C. Virchow, and et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol 136 2015 38 48
5. M. Zureik, C. Neukirch, B. Leynaert, R. Liard, J. Bousquet, and F. Neukirch Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey BMJ 325 2002 411 414
6. G.W. Canonica, F. Tarantini, E. Complati, and M. Penagos Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials Allergy 62 2007 359 366
7. E. Valovirta, S.E. Myrseth, and S. Palkonen The voice of the patients: allergic rhinitis is not a trivial disease Curr Opin Allergy Clin Immunol 8 2008 1 9
8. J. Bousquet, N. Khaltaev, A.A. Cruz, J. Denburg, W.J. Fokkens, A. Togias, and et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 suppl 86 2008 8 160
9. C.E. Pichler, A. Marquardsen, S. Sparholt, H. Lowenstein, A. Bircher, M. Bischof, and et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity Allergy 52 1997 274 283
10. H. Riechelmann, J. Schmutzhard, J.F. van der Werf, A. Distler, and H.A. Kleinjans Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis Am J Rhinol Allergy 24 2010 e104 e109
11. A. Yukselen, S.G. Kendirli, M. Yilmaz, D.U. Altintas, and G.B. Karakoc Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study Int Arch Allergy Immunol 157 2012 288 298
12. G.W. Canonica, L. Cox, R. Pawankar, C.E. Baena-Cagnani, M. Blaiss, S. Bonini, and et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update World Allergy Organ J 7 2014 6
13. M.A. Calderon, T.B. Casale, H.S. Nelson, and P. Demoly An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies J Allergy Clin Immunol 132 2013 1322 1336
14. H. Mosbech, G.W. Canonica, V. Backer, F. de Blay, L. Klimek, L. Broge, and et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms Ann Allergy Asthma Immunol 114 2015 134 140
15. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 2008. Adopted by the WMA General Assembly in Helsinki (1964) and as amended by the WMA General Assembly. http://www.wma.net.
16. ICH. ICH harmonised tripartite guideline topic E6 (R1): guideline for good clinical practice. 1996. http://www.ich.org.
17. E.F. Juniper, A.S. Buist, F.M. Cox, P.J. Ferrie, and D.R. King Validation of a standardized version of the Asthma Quality of Life Questionnaire Chest 115 1999 1265 1270
18. M. Blaiss, J. Maloney, H. Nolte, S. Gawchik, R. Yao, and D.P. Skoner Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents J Allergy Clin Immunol 127 2011 64 71
19. A. Bufe, P. Eberle, E. Franke-Beckmann, J. Funck, M. Kimmig, L. Klimek, and et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy J Allergy Clin Immunol 123 2009 167 173
20. P.S. Creticos, J. Maloney, D.I. Bernstein, T. Casale, A. Kaur, R. Fisher, and et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults J Allergy Clin Immunol 131 2013 1342 1349
21. J. Maloney, D.I. Bernstein, H. Nelson, P. Creticos, J. Hebert, M. Noonan, and et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial Ann Allergy Asthma Immunol 112 2014 146 153
22. H.S. Nelson, H. Nolte, P. Creticos, J. Maloney, J. Wu, and D.I. Bernstein Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults J Allergy Clin Immunol 127 2011 72 80
23. H. Nolte, J. Hebert, G. Berman, S. Gawchik, M. White, A. Kaur, and et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults Ann Allergy Asthma Immunol 110 2013 450 456
24. H. Mosbech, W. Canonica, V. Backer, F. de Blay, L. Klimek, L. Broge, and et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with HDM-allergic asthma and rhinitis symptoms Ann Allergy Asthma Immunol 114 2015 134 140
25. H. Nolte, J. Maloney, H.S. Nelson, D.I. Bernstein, S. Lu, Z. Li, and et al. Dose-related efficacy and onset of action of house dust mite sublingual immunotherapy tablet in an environmental exposure chamber J Allergy Clin Immunol 135 2015 1494 1501.e6
26. K.C. Bergmann, P. Demoly, M. Worm, W.J. Fokkens, T. Carrillo, A. Tabar, and et al. Efficacy and safety of sublingual tablets of house dust mites allergen extracts in adults with allergic rhinitis J Allergy Clin Immunol 133 2014 1608 1614
27. G.W. Canonica, J. Bousquet, T. Casale, R.F. Lockey, C.E. Baena-Cagnani, R. Pawankar, and et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009 World Allergy Org J 2 2009 233 281
28. EMEA. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006[Final]. London, 2008. http://www.ema.europa.eu.
29. M.A. Calderon, D.I. Bernstein, M. Blaiss, J.S. Andersen, and H. Nolte A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis Clin Exp Allergy 44 2014 1228 1239
30. O. Pfaar, J. Kleine-Tebbe, K. Hormann, and L. Klimek Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 31 2011 289 309 x
31. O. Pfaar, P. Demoly, W.R. Gerth van, S. Bonini, J. Bousquet, G.W. Canonica, and et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper Allergy 69 2014 854 867
32. G.W. Canonica, C.E. Baena-Cagnani, J. Bousquet, P.J. Bousquet, R.F. Lockey, H.J. Malling, and et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for Respiratory allergy. A statement of the World Allergy Organization (WAO) taskforce Allergy 62 2007 317 324
33. A. del Cuvillo, J. Sastre, J. Bartra, J. Mullol, I. Davila, J. Montoro, and et al. Placebo effect in clinical trials involving patients with allergic rhinitis J Investig Allergol Clin Immunol 21 suppl 3 2011 40 45
34. M.A. Calderon, L. Cox, T.B. Casale, P. Moingeon, and P. Demoly Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence J Allergy Clin Immunol 129 2012 929 934
35. H. Nelson, M. Blaiss, H. Nolte, S.O. Wurtz, J.S. Andersen, and S.R. Durham Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects Allergy 68 2013 252 255
36. H. Mosbech, R. Deckelmann, F. de Blay, E.A. Pastorello, E. Trebas-Pietras, L.P. Andres, and et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 34 2014 568 575.e7
37. S.R. Durham, W. Emminger, A. Kapp, J.G. De Monchy, S. Rak, G.K. Scadding, and et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial J Allergy Clin Immunol 129 2012 717 725
38. H. Mosbech, G.W. Canonica, V. Backer, F. de Blay, L. Klimek, L. Broge, and et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms Ann Allergy Asthma Immunol 114 2015 134 140
39. U. Meier A note on the power of Fisher's least significant difference procedure Pharm Stat 5 2006 253 263
40. D.B. Rubin Multiple imputation for non response in surveys 1987 John Wiley & Sons New York